Form 6-K Evogene Ltd. For: Sep 15
Tweet
Share
E-mailUNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2022
Commission File Number 001-36187
EVOGENE LTD.
(Translation of Registrant’s Name into English)
13 Gad Feinstein Street, Park Rehovot, Rehovot
P.O.B 4173, Ness Ziona, 7414002, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
CONTENTS
Evogene Ltd. (the “Registrant” or the “Company”) hereby announces that the shareholders of the Company approved all the proposals
brought before the annual general meeting of shareholders held on September 15, 2022 (following a one-week adjournment from the original meeting date) (the “Meeting”), by the respective requisite majority in accordance with the Israeli Companies Law, 5759-1999, and the Company’s articles of association, as described in the Proxy Statement which was attached as Exhibit
99.2 to the Company’s Report of Foreign Private Issuer on Form 6-K, furnished to the Securities and Exchange Commission (“SEC”), on August
3, 2022, and sent in connection with the Meeting.
4,899,609 ordinary shares, representing approximately 12% of the issued and outstanding ordinary shares as of the record date, were present or represented
by proxy at the Meeting.
The contents of this Report of Foreign Private Issuer on Form 6-K (this “Form 6-K”) is incorporated by reference in the registration statements on Form F-3 (SEC File
No. 333-253300), and Form S-8 (SEC File Nos. 333-193788, 333-201443, 333-203856 and 333-259215) of the Company, and will be a part thereof from the date on which this Form 6-K is submitted, to the extent not superseded by documents or reports
subsequently filed or furnished.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to
be signed on its behalf by the undersigned, thereunto duly authorized.
|
Date: September 15, 2022
|
EVOGENE LTD.
(Registrant) By: /s/ Yaron Eldad —————————————— Yaron Eldad Chief Financial Officer |
3
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Biomica to Present at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
- Biophytis Announces New Scientific Advisory Board for its Phase 2 OBA Clinical Study in Obesity
- Biophytis Announces New Scientific Advisory Board for its Phase 2 OBA Clinical Study in Obesity
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
